论文部分内容阅读
关于罗格列酮安全性一直是国际糖尿病学界关注的焦点,以致今年7月FDA咨询委员会的各方面专家,再次开会全面讨论了罗格列酮心血管安全性问题,并最后通过投票表决,有条件保留罗格列酮临床应用。会后美国ADA、AACE和AES三大学会于7月15日发表联合声明,随即GSK于7月22日在北京召开了中国专家的罗格列酮咨询会,现将该会议纪要转发如下,供读者参考。
On the safety of rosiglitazone has been the focus of the international diabetes community, so that in July this year, FDA Advisory Committee of experts in various aspects, met again to discuss the comprehensive cardiovascular safety of rosiglitazone and finally voted, there Conditions to retain the clinical application of rosiglitazone. After the meeting, the three major ADA, AACE and AES institutes in the United States issued a joint statement on July 15, and GSK then convened a rosiglitazone consultation meeting for Chinese experts on July 22 in Beijing. The minutes of the meeting are now forwarded as follows Reader’s reference